BR112015021000A2 - composição de uma distribuição liberação prolongada e método de estabilizar proteínas durante o processo de fabricação - Google Patents

composição de uma distribuição liberação prolongada e método de estabilizar proteínas durante o processo de fabricação

Info

Publication number
BR112015021000A2
BR112015021000A2 BR112015021000A BR112015021000A BR112015021000A2 BR 112015021000 A2 BR112015021000 A2 BR 112015021000A2 BR 112015021000 A BR112015021000 A BR 112015021000A BR 112015021000 A BR112015021000 A BR 112015021000A BR 112015021000 A2 BR112015021000 A2 BR 112015021000A2
Authority
BR
Brazil
Prior art keywords
composition
manufacturing process
proteins during
protein
prolonged release
Prior art date
Application number
BR112015021000A
Other languages
English (en)
Inventor
Wu Cindy
H Tran Simon
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112015021000A2 publication Critical patent/BR112015021000A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

resumo composição de uma distribuição liberação prolongada e método de estabilizar proteínas durante o processo de fabricação tal como aqui descrita, a administração controlada e prolongada de um agente terapêutico, tal como uma proteína através da administração de uma ou mais micropartículas, pode melhorar o tratamento de condições, tais como condições oculares indesejáveis. as microesferas podem ser formuladas para proporcionar uma liberação prolongada de uma proteína, enquanto reduz o número de agregados proteicos, atingindo perfis desejáveis de liberação e aumentando a estabilidade da proteína dentro das formulações de microesferas.
BR112015021000A 2013-03-14 2014-03-13 composição de uma distribuição liberação prolongada e método de estabilizar proteínas durante o processo de fabricação BR112015021000A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361786035P 2013-03-14 2013-03-14
PCT/US2014/026320 WO2014151725A1 (en) 2013-03-14 2014-03-13 Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process

Publications (1)

Publication Number Publication Date
BR112015021000A2 true BR112015021000A2 (pt) 2017-07-18

Family

ID=50483567

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021000A BR112015021000A2 (pt) 2013-03-14 2014-03-13 composição de uma distribuição liberação prolongada e método de estabilizar proteínas durante o processo de fabricação

Country Status (10)

Country Link
US (1) US20140274873A1 (pt)
EP (2) EP2968574A1 (pt)
JP (2) JP6649246B2 (pt)
KR (1) KR20150128857A (pt)
CN (1) CN105188759A (pt)
AU (2) AU2014236938B2 (pt)
BR (1) BR112015021000A2 (pt)
CA (1) CA2902547A1 (pt)
RU (1) RU2720412C2 (pt)
WO (1) WO2014151725A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106076214B (zh) * 2016-07-15 2019-12-17 沈阳化工大学 一种具有核壳结构的海藻酸钙微球制备方法
GB201906835D0 (en) * 2019-05-15 2019-06-26 Ucb Biopharma Sprl Dry microparticles

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
PT814778E (pt) * 1995-03-10 2001-11-30 Roche Diagnostics Gmbh Formas de administracao farmaceuticas contendo polipeptidos sob a forma de microparticulas e processo para a sua preparacao
GB9514285D0 (en) * 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CA2369451C (en) * 1999-04-08 2009-09-22 Genentech, Inc. Composition based on oppositely-charged polypeptides
US6896906B2 (en) * 2000-12-21 2005-05-24 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
EP1436329A4 (en) 2001-09-20 2005-04-27 Alexion Pharma Inc ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
EP1838290A2 (en) * 2005-01-21 2007-10-03 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
US20080095849A1 (en) * 2005-04-25 2008-04-24 Amgen Inc. Peptide sustained release compositions and uses thereof
JP5074750B2 (ja) * 2005-12-07 2012-11-14 一般財団法人化学及血清療法研究所 シクロデキストリン類を含有する液状フィブリノゲン製剤
US8642067B2 (en) * 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2009031011A2 (en) * 2007-09-05 2009-03-12 Pfizer Limited Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine
JP5406049B2 (ja) * 2008-02-05 2014-02-05 協和発酵バイオ株式会社 グルタチオンの保存安定性向上方法
EP2358746B1 (en) * 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
WO2011041642A1 (en) 2009-10-01 2011-04-07 Surmodics Pharmaceuticals, Inc. Microparticle compositions and methods for treating age-related macular degeneration
US9668915B2 (en) * 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant

Also Published As

Publication number Publication date
EP3693021A1 (en) 2020-08-12
AU2019201884A1 (en) 2019-04-11
WO2014151725A1 (en) 2014-09-25
RU2720412C2 (ru) 2020-04-29
KR20150128857A (ko) 2015-11-18
AU2014236938B2 (en) 2018-12-20
CN105188759A (zh) 2015-12-23
US20140274873A1 (en) 2014-09-18
JP2016517418A (ja) 2016-06-16
JP6649246B2 (ja) 2020-02-19
JP2020029466A (ja) 2020-02-27
AU2019201884B2 (en) 2020-08-27
EP2968574A1 (en) 2016-01-20
CA2902547A1 (en) 2014-09-25
RU2015135147A (ru) 2017-04-18
AU2014236938A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
BR112018073699A2 (pt) amino lipídios de sulfonamida catiônica e amino lipídios zwiteriônico anfifílicos
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
MX2017013983A (es) Uso de agentes activos durante tratamientos quimicos.
WO2017059385A8 (en) 11,13-modified saxitoxins for the treatment of pain
BR112018000734A2 (pt) composições tópicas retinoicas
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
IN2014DN09434A (pt)
MX2017012426A (es) Composiciones y metodos para modular la expresion de tmprss6.
GB2541835A (en) Multivesicular liposome formulations of tranexamic acid
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
BR112018009644A2 (pt) micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
BR112015023603A2 (pt) métodos de uso do zscan4 para rejuvenescer células humanas
BR112017016016A2 (pt) composição de suspensão oftálmica
MX2016002408A (es) Metodos para el tratamiento de trastornos oticos pediatricos.
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
CL2017000120A1 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares
AR086956A1 (es) Formulaciones liofilizadas de fgf-18
BR112019017393A2 (pt) formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
BR112015022044A2 (pt) um método de proporcionar neutroproteção ocular
BR112015021000A2 (pt) composição de uma distribuição liberação prolongada e método de estabilizar proteínas durante o processo de fabricação
BR112015022084A2 (pt) composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol
MX2017013879A (es) Composiciones que comprenden anakinra.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/18 (2006.01), A61K 38/00 (2006.01), A61K 4

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2662 DE 11-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.